Skip to main content

Advertisement

SpringerLink
Log in

Complete Pathological Response in a Patient with Metastatic Esophageal Cancer Treated with a Regimen of Capecitabine, Oxaliplatin and Docetaxel: A Case Report

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  3. Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res. 2009;3:S2–5.

    PubMed Central  PubMed  Google Scholar 

  4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.

    Article  CAS  PubMed  Google Scholar 

  5. Wagner AD, Unverzagt S, Grothe W, et al.: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev:CD004064, 2010

  6. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008;2:85–92.

    PubMed Central  PubMed  Google Scholar 

  7. Ban Y, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 2010;376(9742):687–697

    Google Scholar 

  8. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.

    Article  CAS  PubMed  Google Scholar 

  9. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996–2004.

    Article  CAS  PubMed  Google Scholar 

  10. Ross PJ, Hill ME, Norman A, et al. ECF in gastric cancer. J Clin Oncol. 2000;18:3874–5.

    CAS  PubMed  Google Scholar 

  11. Van CE, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.

    Article  Google Scholar 

  12. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

    Article  CAS  PubMed  Google Scholar 

  13. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3210–6.

    Article  CAS  PubMed  Google Scholar 

  14. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205–9.

    Article  CAS  PubMed  Google Scholar 

  15. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.

    Article  CAS  PubMed  Google Scholar 

  16. Amarantidis K, Xenidis N, Chelis L, et al. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Oncology. 2011;80:359–65.

    Article  CAS  PubMed  Google Scholar 

  17. Evans D, Miner T, Akerman P, et al. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol. 2007;30:346–9.

    Article  CAS  PubMed  Google Scholar 

  18. Halmos B, Jia Y, Bokar JA, et al.: A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Invest New Drugs, 2013

  19. Stein A, Arnold D, Thuss-Patience PC, et al.: Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study. Acta Oncol, 2013 (In press.)

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. New York University School of Medicine, New York, NY, USA

    Nagashree Seetharamu, Jonathan Melamed, George Miller & Gerald Villanueva

  2. Columbia University Medical Center, New York, NY, USA

    Heidrun Rotterdam, Tamas Gonda & Balazs Halmos

  3. New York University Cancer Institute, 550, First Avenue BCD 556, New York, NY, 10016, USA

    Nagashree Seetharamu

Authors
  1. Nagashree Seetharamu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Melamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heidrun Rotterdam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamas Gonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerald Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Balazs Halmos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nagashree Seetharamu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seetharamu, N., Melamed, J., Miller, G. et al. Complete Pathological Response in a Patient with Metastatic Esophageal Cancer Treated with a Regimen of Capecitabine, Oxaliplatin and Docetaxel: A Case Report. J Gastrointest Canc 45 (Suppl 1), 108–111 (2014). https://doi.org/10.1007/s12029-013-9575-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-013-9575-6

Keywords

Search

Navigation